Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Chen, Xing Lin ^a   Lei, Ying Hong ^a   Liu, Cun Fei ^b   Yang, Qun Fang ^a   Zuo, Pei Yuan ^a   Liu, Cheng Yun ^a   Chen, Chang Zhong ^c   Liu, Yu Wei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

ARTICLE; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY CARCINOMA; LIVER CANCER; LOW DRUG DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MYOCARDIAL ISCHEMIA; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84879260188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066721     Document Type: Article

References (41)

1. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
2. Hicklin DJ, Ellis LM, (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
3. Motzer RJ, Bukowski RM, (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24: 5601-5608.
4. Jain RK, Duda DG, Clark JW, Loeffler JS, (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
5. Kerbel R, Folkman J, (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739.
6. Ferrara N, Hillan KJ, Gerber HP, Novotny W, (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400.
7. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
9. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, et al. (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508.
10. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
11. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697-3705.
12. Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, et al. (2012) Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 7: e35629.
13. Gordon MS, Cunningham D, (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69Suppl 3: 25-33.
14. Ranpura V, Hapani S, Chuang J, Wu S, (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49: 287-297.
15. Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, et al. (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol. 23: 1531-1536.
16. Meyerhardt JA, Li L, Sanoff HK, Carpenter WT, Schrag D, (2012) Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 30: 608-615.
17. Kemeny NE, Schwartz L, Gonen M, Yopp A, Gultekin D, et al. (2011) Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 80: 153-159.
18. Loke YK PDHA (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0.
19. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
20. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
21. Sterne JA, Egger M, Smith GD, (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101-105.
22. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, et al. (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 2137-2143.
23. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, et al. (2009) Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27: 3385-3390.
24. Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, et al. (2009) Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 15: 449-456.
25. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434.
26. Yeh ET, Bickford CL, (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53: 2231-2247.
27. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, et al. (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109: 3122-3131.
28. des Guetz G, Uzzan B, Chouahnia K, Morere JF, (2011) Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol 6: 197-202.
29. Zhu X, Wu S, Dahut WL, Parikh CR, (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193.
30. Senkus E, Jassem J, (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 37: 300-311.
31. Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, et al. (2011) Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol 80: 369-379.
32. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111.
33. Cella D, Wang M, Wagner L, Miller K, (2011) Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat 130: 855-861.
34. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, et al. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377: 1846-1854.
35. Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, et al. (2010) A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer 10: 545.
36. Senkus E, Jassem J, (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 37: 300-311.
37. Gonzalez-Pacheco FR, Deudero JJ, Castellanos MC, Castilla MA, Alvarez-Arroyo MV, et al. (2006) Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol 291: H1395-H1401.
38. Zachary I, Gliki G, (2001) Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 49: 568-581.
39. Stone JR, Collins T, (2002) The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 9: 231-238.
40. Cohen MH, Gootenberg J, Keegan P, Pazdur R, (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12: 356-361.
41. Macedo LT, Da CLA, Sasse AD, (2012) Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 12: 89.